Total GAAP quarterly product and service revenues increased approximately 50% to $127 million
Makena® (hydroxyprogesterone caproate injection) and Feraheme® (ferumoxytol) achieve record sales
Significant progress on next generation Makena and Feraheme development programs
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the second quarter ended June 30, 2016. Total product and service revenues for the second quarter of 2016 increased approximately 50% to $127.4 million. This increase was driven by record sales of Makena and Feraheme and the addition of Cord Blood Registry® (CBR) to the company’s product portfolio in August of 2015. The company reported second quarter 2016 operating income of $18.1 million and a net loss of $0.6 million. Non-GAAP adjusted EBITDA for the second quarter of 2016 increased 24% to $64.6 million1 versus the same period in 2015. After deducting cash interest expense from adjusted EBITDA, the company generated second quarter 2016 non-GAAP net income of $50.3 million.1
“Strong execution, including the recent successful launch of the single-dose, preservative-free formulation of Makena and expanded use of our Makena @Home service, drove 21% sales growth in the second quarter over the first quarter of 2016,” stated William Heiden, AMAG’s chief executive officer. “In addition to solid commercial performance during the quarter, we made further progress on both our Feraheme and Makena next-generation development programs.”
1 See summaries of GAAP to non-GAAP adjustments at the conclusion of this press release.
Makena Next Generation Development Update
AMAG has completed pilot pharmacokinetic (PK) studies and is preparing for the initiation of a definitive PK study later this year for the Makena subcutaneous auto-injector device. The company recently met with the U.S. Food and Drug Administration (FDA) to review its planned supplemental new drug application (sNDA) filing for this new Makena product. Based on those discussions, the company has accelerated its plan to conduct a comparative pain study concurrently with the definitive PK study so that it can include the pain data in the sNDA submission. Successfully demonstrating a reduction in pain will allow the company to apply for seven years of orphan drug exclusivity on the drug-device combination. Orphan drug exclusivity is based on the FDA’s assessment of clinical superiority as measured by a significant improvement in safety or efficacy over the existing standard of care. This exclusivity, along with the already issued patents on the auto-injector device and a filed patent application on the route of administration, would provide multiple layers of protection. The inclusion of clinical pain data in the sNDA will likely result in a 10 month regulatory review timeline. The company’s timeline to file the sNDA in the second quarter of 2017 remains unchanged, with an anticipated FDA approval in the first quarter of 2018.
“We believe that submitting the pain data with the sNDA filing is the best strategy to extend and protect the Makena franchise and secure our leadership position in this market for many years to come,” said Mr. Heiden.
Second Quarter 2016 and Recent Business Highlights
- Delivered record net product and service revenues of $127.4 million in the second quarter of 2016, compared with $84.7 million in the same period last year. This increase of approximately 50% was driven by record sales of both Makena and Feraheme and the addition of CBR.
- Achieved record Makena sales of $78.4 million in the second quarter of 2016, compared with $63.6 million in the same period last year. This 23% growth in sales was driven exclusively by an increase in volume. This growth resulted in Makena market share of 37%, four percentage points over the first quarter of 2016.
- Generated a record $24.3 million of Feraheme sales in the second quarter of 2016, or 18% growth over the same period last year, the majority of which was driven by volume.
- Increased non-GAAP CBR revenue by 5%1 over the first quarter of 2016 due to improved net revenue per new customer. In addition, new customer volume has stabilized on a sequential quarter basis.
- Received approval from the FDA in July 2016 of an additional source of supply for the single-dose, preservative-free formulation of Makena.
- Completed pilot PK studies for the Makena subcutaneous auto-injector and plans to conduct a pain study designed to establish clinical superiority over the current intramuscular injection concurrently with the definitive PK study.
- Exceeded forecasted patient enrollment to date in the company’s head-to-head, Phase 3 clinical trial evaluating Feraheme in adults with iron deficiency anemia (IDA). This study, which is now approximately 25% enrolled, is intended to support an sNDA filing to broaden the use of Feraheme beyond the current chronic kidney disease (CKD) indication to include all adult IDA patients who have failed or cannot tolerate oral iron treatment. The company anticipates filing an sNDA to broaden the Feraheme label in 2017.
- Generated an increase in cash, cash equivalents and investments of $80.1 million in the first half of 2016 to $546.5 million, net of $20.0 million utilized to repurchase the company’s common stock and $8.8 million to repay debt.
Second Quarter Ended June 30, 2016 (unaudited)
Financial Results (GAAP Basis)
Total revenues for the second quarter of 2016 were $127.4 million, compared with $123.9 million in the second quarter of 2015. Included in last year’s second quarter results was $39.2 million of collaboration revenue primarily related to the one-time acceleration of previously deferred revenue from the termination of the company’s ex-US ferumoxytol marketing partnership agreement. Net product and service revenues totaled $127.4 million in the second quarter of 2016, compared with $84.7 million in the same period last year. This increase is related to record sales of both Makena and Feraheme and the addition of CBR, which AMAG purchased in August 2015. Net product sales of Makena increased to $78.4 million in the second quarter of 2016, compared with $63.6 million in the same period last year. This growth in Makena sales was driven by a 24% increase in volume, primarily as a result of the successful launch of the single-dose, preservative-free formulation and increased enrollments in the company’s Makena @Home program. Sales of Feraheme and MuGard® totaled $24.6 million in the second quarter of 2016, compared with $21.1 million in the second quarter of 2015. Service revenue from CBR, on a GAAP basis, totaled $24.4 million in the second quarter of 2016.
Total costs and expenses, including costs of product sales and services, totaled $109.3 million for the second quarter of 2016, compared with $62.8 million for the same period in 2015. The increase in operating expenses in 2016 was related to: 1) the cost of services and operating expenses associated with CBR, which the company acquired in the third quarter of 2015, 2) a $15.7 million impairment charge of the MuGard intangible asset partially offset by a $5.6 million reduction in the contingent consideration liability, both due to the lack of broad reimbursement and insurance coverage for the product, 3) higher non-cash amortization of intangible assets from the company’s acquisitions, and 4) higher research and development (R&D) costs that included initiation of the company’s Phase 3 clinical trial to broaden the use of Feraheme to include all adult IDA patients and costs to support the company’s Makena subcutaneous auto-injector development program.
Second quarter 2016 operating income totaled $18.1 million, compared with $61.1 million in the second quarter of last year. The company reported a net loss of $0.6 million, or ($0.02) per basic share and diluted share, for the second quarter of 2016, compared with net income of $33.3 million, or $1.09 per basic share and $0.82 per diluted share, for the same period in 2015. Both operating income and net income in the second quarter of 2015 benefitted from $39.2 million of collaboration revenue from a former ex-US licensing partner, which includes $5.6 million of cash received.
Balance Sheet Highlights
The company’s cash, cash equivalents and investments increased by $80.1 million in the first half of 2016 to approximately $546.5 million, net of $20.0 million utilized to repurchase the company’s common stock and $8.8 million to repay debt. Total debt (principal amount outstanding), including $200 million of convertible debt, was approximately $1.04 billion as of June 30, 2016.
“We are pleased with our financial performance during the first half of 2016,” stated Ted Myles, chief financial officer of AMAG. “With increasing revenue and a disciplined approach to expense management, our business successfully generated significant EBITDA and cash flows. This further strengthens our balance sheet giving us additional capacity to pursue our portfolio expansion strategy.”
Financial Results (Non-GAAP Basis)1,2
Non-GAAP revenues totaled $132.5 million in the second quarter of 2016, up from $90.3 million in the second quarter of 2015. Non-GAAP CBR revenue totaled $29.4 million in the second quarter of 2016. The difference between GAAP and non-GAAP revenue for CBR represents purchase accounting adjustments related to deferred revenue. Non-GAAP revenue in 2015 excluded certain non-cash revenue related to the termination of the company’s ex-US ferumoxytol marketing agreement with its former partner.
Total costs and expenses, including costs of product sales and services, on a non-GAAP basis totaled $67.8 million in the second quarter of 2016, compared with total costs and expenses of $38.3 million in the same period in 2015. Non-GAAP adjusted EBITDA for the second quarter of 2016 was $64.6 million, compared with $52.1 million for the same period in 2015. Included in second quarter 2015 adjusted EBITDA was the $5.6 million cash portion of collaboration revenue recognized in connection with the termination of the company’s ex-US ferumoxytol marketing partnership agreement.
After deducting cash interest expense from adjusted EBITDA, the company generated second quarter 2016 non-GAAP net income of $50.3 million, or $1.47 per non-GAAP basic share and $1.45 per non-GAAP diluted share. In the second quarter of 2015, non-GAAP net income totaled $44.8 million, or $1.46 per non-GAAP basic share and $1.12 per non-GAAP diluted share.
2 See share count reconciliation at the conclusion of this press release.
2016 Financial Guidance3
| $ in millions | 2016 GAAP Guidance | 2016 Non-GAAP Guidance | |||
| Makena sales | $310 - $340 | $310 - $340 | |||
| Feraheme and MuGard sales | $95 - $105 | $95 - $105 | |||
| CBR revenue | $98 - $108 | $115 - $125 | |||
| Total revenue | $503 - $553 | $520 - $570 | |||
| Net income | $0 - $30 | $195 - $225 | |||
| Operating income | $93 - $123 | N/A | |||
| Adjusted EBITDA | N/A | $255 - $285 |
Conference Call and Webcast Access
AMAG Pharmaceuticals, Inc. will host a conference call and webcast with slides today at 8:00 a.m. ET, during which management will discuss the company’s financial and operating results and recent developments. To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on August 9, 2016 through midnight on August 18, 2016. To access a replay of the conference call, dial (855) 859-2056 from the United States or (404) 537-3406 for international access. The pass code for the live call and the replay is 45782895.
The call will be webcast with slides and accessible through the Investors section of the company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on August 9, 2016 through midnight on September 9, 2016.
Use of Non-GAAP Financial Measures
AMAG has presented certain non-GAAP financial measures, including non-GAAP revenue, non-GAAP costs and expenses, non-GAAP adjusted EBITDA (earnings before income taxes, depreciation and amortization), non-GAAP net income, non-GAAP basic and diluted net income per share, and non-GAAP weighted average basic and diluted shares outstanding. These non-GAAP financial measures exclude certain amounts, revenue, expenses, income or dilutive shares from the corresponding financial measures determined in accordance with accounting principles generally accepted in the U.S. (GAAP). Due to the adjustments made to GAAP net income (loss) and GAAP net income (loss) per share to calculate non-GAAP adjusted net income and non-GAAP net income per share, the non-GAAP measures are higher than GAAP net income (loss) and GAAP net income (loss) per share.
Management believes this non-GAAP information is useful for investors, taken in conjunction with AMAG’s GAAP financial statements, because it provides greater transparency regarding AMAG’s operating performance and prospects for future performance and allows investors to better compare performance over different periods. Management uses these measures, among other factors, to assess and analyze operational results and trends and to make financial and operational decisions, including in compensation decisions. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of AMAG’s operating results as reported under GAAP, not as a substitute for GAAP, and AMAG encourages investors to review its consolidated financial statements and publicly filed reports in their entirety. In addition, these non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Further, non-GAAP net income and non-GAAP net income per share should not be considered measures of our liquidity. The determination of the amounts that are excluded from non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. Reconciliations between these non-GAAP financial measures and the most comparable GAAP financial measures are included in the tables accompanying this press release after the unaudited condensed consolidated financial statements.
3 See reconciliation of 2016 financial guidance of non-GAAP adjusted EBITDA and non-GAAP net income at the conclusion of this press release. Non-GAAP CBR revenue and non-GAAP total revenue reflect the addition of $17 million related to purchase accounting adjustments for deferred revenue in connection with the CBR acquisition.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
About Makena® (hydroxyprogesterone caproate injection)
Makena® is a progestin indicated to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth.
The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.
Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.
Makena should not be used in women with any of the following conditions: blood clots or other blood clotting problems, breast cancer or other hormone-sensitive cancers, or history of these conditions; unusual vaginal bleeding not related to the current pregnancy, yellowing of the skin due to liver problems during pregnancy, liver problems, including liver tumors, or uncontrolled high blood pressure.
Before patients receive Makena, they should tell their healthcare provider if they have an allergy to hydroxyprogesterone caproate, castor oil, or any of the other ingredients in Makena; diabetes or prediabetes, epilepsy, migraine headaches, asthma, heart problems, kidney problems, depression, or high blood pressure.
In one clinical study, certain complications or events associated with pregnancy occurred more often in women who received Makena. These included miscarriage (pregnancy loss before 20 weeks of pregnancy), stillbirth (fetal death occurring during or after the 20th week of pregnancy), hospital admission for preterm labor, preeclampsia (high blood pressure and too much protein in the urine), gestational hypertension (high blood pressure caused by pregnancy), gestational diabetes, and oligohydramnios (low amniotic fluid levels).
Makena may cause serious side effects including blood clots, allergic reactions, depression, and yellowing of the skin and the whites of the eyes. The most common side effects of Makena include injection site reactions (pain, swelling, itching, bruising, or a hard bump), hives, itching, nausea, and diarrhea.
For additional product information, including full prescribing information, please visit www.makena.com.
About Feraheme® (ferumoxytol)
Feraheme received marketing approval from the FDA on June 30, 2009 for the treatment of IDA in adult CKD patients and was commercially launched by AMAG in the U.S. shortly thereafter. Ferumoxytol is protected in the U.S. by six issued patents covering the composition and dosage form of the product. Each issued patent is listed in the FDA’s Orange Book, the last of which expires in June 2023.
Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme. Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest. Feraheme is contraindicated in patients with a known hypersensitivity to Feraheme or any of its components, or a history of allergic reaction to any intravenous iron product.
For additional product information, please see full Prescribing Information, including Boxed Warning, available at www.feraheme.com.
About Cord Blood Registry® (CBR)
CBR is the world’s largest private newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 600,000 umbilical cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with reputable research institutions on FDA-regulated clinical trials for conditions that have no cure today. For more information, visit www.cordblood.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, expectations for AMAG’s next generation development programs for Makena, including the FDA review period for the auto-injector, the anticipated timing to file a sNDA, the likelihood and timing of an anticipated approval for the subcutaneous auto-injector, AMAG’s intention to conduct a comparative pain study, AMAG’s ability to successfully demonstrate clinical superiority over the intramuscular injection by demonstrating a reduction in pain and to obtain orphan drug exclusivity for the drug-device combination and AMAG’s belief that submission of the pain data in the sNDA is the best strategy to protect the Makena franchise; expectations for AMAG’s Phase 3 clinical trial for the broader indication for Feraheme, including the expected timing of an sNDA submission; AMAG’s 2016 financial guidance, including GAAP and non-GAAP revenues, GAAP operating income, non-GAAP adjusted EBITDA and GAAP and non-GAAP net income; AMAG’s belief that the generation of significant EBITDA and cash flows in the first half of 2016 provides it with additional capacity to pursue its portfolio expansion strategy; and beliefs that newborn stem cells have the potential to play a valuable role in the development of regenerative medicine are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2015, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and subsequent filings with the SEC. Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® and Feraheme® are registered trademark of AMAG Pharmaceuticals, Inc. MuGard® is a registered trademark of Abeona Therapeutics, Inc. Makena® is a registered trademark of AMAG Pharmaceuticals IP, Ltd. Cord Blood Registry® and CBR® are registered trademarks of CBR Systems, Inc.
– Tables Follow –
| AMAG Pharmaceuticals, Inc. | |||||||||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||||||||
| (unaudited, amounts in thousands, except for per share data) | |||||||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||||||
| June 30, | June 30, | ||||||||||||||||||||
| 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||
| Revenues: | |||||||||||||||||||||
| Makena | $ | 78,406 | $ | 63,574 | $ | 143,438 | $ | 119,103 | |||||||||||||
| Feraheme/MuGard | 24,577 | 21,078 | 49,109 | 42,964 | |||||||||||||||||
| Cord Blood Registry | 24,379 | — | 43,898 | — | |||||||||||||||||
| License fee, collaboration and other revenues | 57 | 39,232 | 273 | 51,322 | |||||||||||||||||
| Total revenues | 127,419 | 123,884 | 236,718 | 213,389 | |||||||||||||||||
| Operating costs and expenses: | |||||||||||||||||||||
| Cost of product sales | 21,937 | 19,679 | 40,236 | 40,705 | |||||||||||||||||
| Cost of services | 5,195 | — | 10,721 | — | |||||||||||||||||
| Research and development expenses | 14,234 | 8,184 | 28,463 | 15,172 | |||||||||||||||||
| Selling, general and administrative expenses | 51,924 | 31,801 | 115,098 | 63,913 | |||||||||||||||||
| Impairment charges of intangible assets | 15,963 | — | 15,963 | — | |||||||||||||||||
| Acquisition-related costs | — | 2,653 | — | 2,653 | |||||||||||||||||
| Restructuring expenses | 89 | 443 | 712 | 1,014 | |||||||||||||||||
| Total costs and expenses | 109,342 | 62,760 | 211,193 | 123,457 | |||||||||||||||||
| Operating income | 18,077 | 61,124 | 25,525 | 89,932 | |||||||||||||||||
| Other income (expense): | |||||||||||||||||||||
| Interest expense | (18,250 | ) | (10,205 | ) | (36,693 | ) | (20,572 | ) | |||||||||||||
| Interest and dividend income | 773 | 372 | 1,481 | 443 | |||||||||||||||||
| Other income (expense) | — | 2 | 220 | 2 | |||||||||||||||||
| Total other income (expense) | (17,477 | ) | (9,831 | ) | (34,992 | ) | (20,127 | ) | |||||||||||||
| Income (loss) before income taxes | 600 | 51,293 | (9,467 | ) | 69,805 | ||||||||||||||||
| Income tax expense (benefit) | 1,196 | 18,035 | (1,344 | ) | 23,643 | ||||||||||||||||
| Net income (loss) | $ | (596 | ) | $ | 33,258 | $ | (8,123 | ) | $ | 46,162 | |||||||||||
| Net income (loss) per share | |||||||||||||||||||||
| Basic | $ | (0.02 | ) | $ | 1.09 | $ | (0.24 | ) | $ | 1.60 | |||||||||||
| Diluted | $ | (0.02 | ) | $ | 0.82 | $ | (0.24 | ) | $ | 1.23 | |||||||||||
| Weighted average shares outstanding used to compute net income (loss) per share: | |||||||||||||||||||||
| Basic | 34,223 | 30,636 | 34,481 | 28,934 | |||||||||||||||||
| Diluted | 34,223 | 43,181 | 34,481 | 40,791 | |||||||||||||||||
| AMAG Pharmaceuticals, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (unaudited, amounts in thousands) | |||||||
| June 30, 2016 | December 31, 2015 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 251,110 | $ | 228,705 | |||
| Investments | 295,359 | 237,626 | |||||
| Accounts receivable, net | 66,086 | 85,678 | |||||
| Inventories | 39,564 | 40,645 | |||||
| Receivable from collaboration | — | 428 | |||||
| Prepaid and other current assets | 13,437 | 13,592 | |||||
| Total current assets | 665,556 | 606,674 | |||||
| Property, plant and equipment, net | 27,173 | 28,725 | |||||
| Goodwill | 639,484 | 639,188 | |||||
| Intangible assets, net | 1,144,858 | 1,196,771 | |||||
| Restricted cash | 2,593 | 2,593 | |||||
| Other long-term assets | 1,146 | 2,259 | |||||
| Total assets | $ | 2,480,810 | $ | 2,476,210 | |||
| Liabilities and stockholders’ equity: | |||||||
| Accounts payable | $ | 8,653 | $ | 4,906 | |||
| Accrued expenses | 107,599 | 106,363 | |||||
| Current portion of long-term debt | 49,610 | 17,500 | |||||
| Current portion of acquisition-related contingent consideration | 98,703 | 96,967 | |||||
| Deferred revenues | 32,499 | 20,185 | |||||
| Total current liabilities | 297,064 | 245,921 | |||||
| Long-term liabilities: | |||||||
| Long-term debt, net | 764,543 | 803,669 | |||||
| Convertible 2.5% notes, net | 174,953 | 170,749 | |||||
| Acquisition-related contingent consideration | 125,106 | 125,592 | |||||
| Deferred tax liabilities | 188,852 | 189,145 | |||||
| Deferred revenues | 9,983 | 5,093 | |||||
| Other long-term liabilities | 4,142 | 3,777 | |||||
| Total liabilities | 1,564,643 | 1,543,946 | |||||
| Total stockholders’ equity | 916,167 | 932,264 | |||||
| Total liabilities and stockholders’ equity | $ | 2,480,810 | $ | 2,476,210 | |||
| AMAG Pharmaceuticals, Inc. | ||||||||||||||||||||
| Reconciliation of Non-GAAP Adjustments to Net Income | ||||||||||||||||||||
| (unaudited, amounts in thousands) | ||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||
| June 30, 2016 | June 30, 2015 | June 30, 2016 | June 30, 2015 | |||||||||||||||||
| GAAP revenues | $ | 127,419 | $ | 123,884 | $ | 236,718 | $ | 213,389 | ||||||||||||
| Service revenues | 5,053 | 4 | — | 13,614 | 4 | — | ||||||||||||||
| License fee, collaboration and other revenues | — | (33,563 | ) | 5 | — | (39,965 | ) | 5 | ||||||||||||
| Non-GAAP revenues | 132,472 | 90,321 | 250,332 | 173,424 | ||||||||||||||||
| GAAP CBR revenues | 24,379 | — | 43,898 | — | ||||||||||||||||
| Service revenues | 5,053 | 4 | — | 13,614 | 4 | — | ||||||||||||||
| Non-GAAP CBR revenues | 29,432 | — | 57,512 | — | ||||||||||||||||
| GAAP costs of product sales and services | 27,132 | 19,679 | 50,957 | 40,705 | ||||||||||||||||
| Cost of product sales | (17,627 | ) | 6 | (16,521 | ) | 6 | (32,236 | ) | 6 | (34,261 | ) | 6 | ||||||||
| Cost of services | (353 | ) | 7 | — | (713 | ) | 7 | — | ||||||||||||
| Non-GAAP costs of product sales and services | 9,152 | 3,158 | 18,008 | 6,444 | ||||||||||||||||
| GAAP costs and expenses | 109,342 | 62,760 | 211,193 | 123,457 | ||||||||||||||||
| Cost of product sales | (17,627 | ) | 6 | (16,521 | ) | 6 | (32,236 | ) | 6 | (34,261 | ) | 6 | ||||||||
| Cost of services | (353 | ) | 7 | — | (713 | ) | 7 | — | ||||||||||||
| Research and development | (1,867 | ) | 8 | (1,197 | ) | 8 | (2,641 | ) | 8 | (1,691 | ) | 8 | ||||||||
| Selling, general and administrative | (5,605 | ) | 9 | (3,679 | ) | 9 | (20,725 | ) | 9 | (9,865 | ) | 9 | ||||||||
| Impairment charges of intangible assets | (15,963 | ) | 10 | — | (15,963 | ) | 10 | — | ||||||||||||
| Acquisition-related | — | (2,653 | ) | 11 | — | (2,653 | ) | 11 | ||||||||||||
| Restructuring | (89 | ) | 12 | (443 | ) | 12 | (712 | ) | 12 | (1,014 | ) | 12 | ||||||||
| Non-GAAP costs and expenses | 67,838 | 38,267 | 138,203 | 73,973 | ||||||||||||||||
| GAAP other income (expense) | (17,477 | ) | (9,831 | ) | (34,992 | ) | (20,127 | ) | ||||||||||||
| Non-cash interest expense | 3,104 | 13 | 2,944 | 13 | 6,162 | 13 | 5,830 | 13 | ||||||||||||
| Income tax expense (benefit) | 1,196 | 14 | 17,655 | 14 | (1,344 | ) | 14 | 23,025 | 14 | |||||||||||
| Non-GAAP other income (expense) | (13,177 | ) | 10,768 | (30,174 | ) | 8,728 | ||||||||||||||
| GAAP net income (loss) | (596 | ) | 33,258 | (8,123 | ) | 46,162 | ||||||||||||||
| Total adjustments | 50,857 | 11,529 | 91,422 | 38,374 | ||||||||||||||||
| Non-GAAP net income (loss) | 50,261 | 44,787 | 83,299 | 84,536 | ||||||||||||||||
4 Represents purchase accounting adjustments related to deferred revenue in connection with the CBR acquisition.
5 Represents adjustments to exclude certain non-cash revenue associated with the 2014 termination of the company’s ex-US ferumoxytol marketing agreement.
6 Adjustments to eliminate the following: (i) non-cash step-up of inventory from purchase accounting; (ii) amortization expense related to intangible assets; (iii) depreciation expense; and (iv) stock-based compensation expense.
7 Adjustments to eliminate depreciation expense.
8 Adjustments to eliminate the following: (i) non-cash step-up of inventory used in research and development from purchase accounting; (ii) depreciation expense; and (iii) stock-based compensation expense.
9 Adjustments to eliminate the following: (i) non-cash adjustments related to contingent consideration; (ii) amortization expense related to intangible assets; (iii) depreciation expense; and (iv) stock-based compensation expense.
10 Impairment expense of $15.7 million related to the MuGard Intangible Asset and $0.2 million related to the favorable lease intangible asset
11 Adjustments to eliminate one-time costs related to Cord Blood Registry acquisition.
12 Adjustments to eliminate non-recurring restructuring costs.
13 Adjustments to eliminate non-cash interest expense.
14 Adjustments to eliminate non-cash income tax expense (benefit).
| AMAG Pharmaceuticals, Inc. | |||||||||||||||||||
| Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income to Non-GAAP Adjusted EPS | |||||||||||||||||||
| (unaudited, amounts in thousands, except per share data) | |||||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||||
| June 30, 2016 | June 30, 2015 | June 30, 2016 | June 30, 2015 | ||||||||||||||||
| GAAP Net Income (Loss) | $ | (596 | ) | $ | 33,258 | $ | (8,123 | ) | $ | 46,162 | |||||||||
| Adjustments: | |||||||||||||||||||
| Interest expense | 17,477 | 9,831 | 34,993 | 20,127 | |||||||||||||||
| Provision for income tax | 1,196 | 18,035 | (1,344 | ) | 23,643 | ||||||||||||||
| Operating income | 18,077 | 61,124 | 25,526 | 89,932 | |||||||||||||||
| Purchase accounting adjustments related to CBR deferred revenue | 5,053 | — | 13,614 | — | |||||||||||||||
| Non-cash collaboration revenue | — | (33,563 | ) | — | (39,965 | ) | |||||||||||||
| Depreciation and intangible asset amortization | 21,587 | 13,549 | 40,431 | 25,164 | |||||||||||||||
| Non-cash inventory step-up adjustments | 2,344 | 3,643 | 3,144 | 9,826 | |||||||||||||||
| Stock-based compensation | 5,178 | 4,015 | 11,341 | 6,684 | |||||||||||||||
| Adjustments to contingent consideration | (3,657 | ) | (960 | ) | 1,399 | 1,639 | |||||||||||||
| Impairment charges of intangible assets | 15,963 | — | 15,963 | — | |||||||||||||||
| Acquisition-related costs | — | 2,834 | — | 2,834 | |||||||||||||||
| Restructuring costs | 89 | 1,412 | 712 | 3,337 | |||||||||||||||
| Non-GAAP adjusted EBITDA | 64,634 | 52,054 | 112,130 | 99,451 | |||||||||||||||
| Cash interest | (14,373 | ) | (6,887 | ) | (28,831 | ) | (14,297 | ) | |||||||||||
| Cash taxes | — | (380 | ) | — | (618 | ) | |||||||||||||
| Non-GAAP Net Income | $ | 50,261 | $ | 44,787 | $ | 83,299 | $ | 84,536 | |||||||||||
| Basic: | |||||||||||||||||||
| GAAP net income (loss) per share - Basic | $ | (0.02 | ) | $ | 1.09 | $ | (0.24 | ) | $ | 1.60 | |||||||||
| Shares used in GAAP per share computation | 34,223 | 30,636 | 34,481 | 28,934 | |||||||||||||||
| Non-GAAP net income per share - Basic | $ | 1.47 | $ | 1.46 | $ | 2.42 | $ | 2.92 | |||||||||||
| Shares used in non-GAAP per share computation | 34,223 | 30,636 | 34,481 | 28,934 | |||||||||||||||
| Diluted: | |||||||||||||||||||
| GAAP net income (loss) per share - Diluted | $ | (0.02 | ) | $ | 0.82 | $ | (0.24 | ) | $ | 1.23 | |||||||||
| Shares used in GAAP per share computation | 34,223 | 43,181 | 34,481 | 40,791 | |||||||||||||||
| Non-GAAP net income per share - Diluted | $ | 1.45 | $ | 1.12 | $ | 2.39 | $ | 2.27 | |||||||||||
| Shares used in non-GAAP per share computation | 34,607 | 40,002 | 34,839 | 37,182 | |||||||||||||||
| AMAG Pharmaceuticals, Inc. | ||||
| Reconciliation of 2016 Financial Guidance of Non-GAAP Adjusted EBITDA and Non-GAAP Net Income | ||||
| (unaudited, amounts in millions) | ||||
| 2016 | ||||
| Financial | ||||
| Guidance | ||||
| GAAP Net Income | $0 - $30 | |||
| Adjustments: | ||||
| Interest expense | 73 | |||
| Provision for income tax | 20 | |||
| Operating income | $93 - $123 | |||
| Purchase accounting adjustments related to CBR deferred revenue | 17 | |||
| Depreciation and intangible asset amortization | 91 | |||
| Non-cash inventory step-up adjustments | 5 | |||
| Stock-based compensation | 26 | |||
| Adjustments to contingent consideration | 6 | |||
| Impairment charges of intangible assets | 16 | |||
| Restructuring costs | 1 | |||
| Non-GAAP adjusted EBITDA | $255 - $285 | |||
| Cash interest | (60 | ) | ||
| Non-GAAP Net Income | $195 - $225 | |||
| AMAG Pharmaceuticals, Inc. | |||||||||||||
| Share Count Reconciliation | |||||||||||||
| (unaudited, amounts in millions) | |||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||
| June 30, 2016 | June 30, 2015 | June 30, 2016 | June 30, 2015 | ||||||||||
| Weighted average basic shares outstanding | 34.2 | 30.6 | 34.5 | 28.9 | |||||||||
| Employee equity incentive awards | — | 15 | 1.8 | — | 15 | 1.6 | |||||||
| Convertible notes | — | 15 | 7.4 | — | 15 | 7.4 | |||||||
| Warrants | — | 15 | 3.4 | — | 15 | 2.9 | |||||||
| GAAP diluted shares outstanding | 34.2 | 43.2 | 34.5 | 40.8 | |||||||||
| Employee equity incentive awards | 0.4 | 16 | — | 0.3 | 16 | — | |||||||
| Effect of bond hedge and warrants | — | (3.2 | ) | 17 | — | (3.6 | ) | 17 | |||||
| Non-GAAP diluted shares outstanding | 34.6 | 40.0 | 34.8 | 37.2 | |||||||||
15 Employee equity incentive awards, Convertible notes and Warrants would be anti-dilutive in this period utilizing the “if-converted” method, which adjusts net income for the after-tax interest expense applicable to the convertible notes.
16 Reflects the Non-GAAP dilutive impact of the employee equity incentive awards.
17 Reflects the impact of the non-GAAP benefit of the bond hedge and warrants.